Comparative Pharmacology
Head-to-head clinical analysis: KANTREX versus TOBRAMYCIN AND DEXAMETHASONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KANTREX versus TOBRAMYCIN AND DEXAMETHASONE.
KANTREX vs TOBRAMYCIN AND DEXAMETHASONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, inhibiting bacterial protein synthesis and causing mRNA misreading.
Tobramycin: aminoglycoside antibiotic that binds to bacterial 30S ribosomal subunit, inhibiting protein synthesis and causing misreading of mRNA. Dexamethasone: corticosteroid that suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and stabilizing lysosomal membranes.
15 mg/kg/day IM or IV divided every 8-12 hours (not to exceed 1.5 g/day)
1-2 drops of suspension into the conjunctival sac every 4-6 hours; in severe cases, every 2 hours initially, then taper.
None Documented
None Documented
2-3 hours (normal renal function); prolonged to 30-50 hours in anuria; clinically significant accumulation in renal impairment requires monitoring
Tobramycin: 2-3 hours in patients with normal renal function; prolonged (24-60 hours) in renal impairment. Dexamethasone: 3-5 hours in adults; prolonged in hepatic impairment.
Renal: 80-100% as unchanged drug via glomerular filtration; fecal: <1%
Tobramycin is eliminated primarily by the kidneys via glomerular filtration, with 80-90% of an absorbed dose excreted unchanged in urine over 24 hours; minor biliary/fecal excretion (<1%). Dexamethasone is metabolized in the liver and excreted in urine (65%) and feces (35%) as metabolites.
Category C
Category D/X
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic